ALKS

Alkermes plc (ALKS) | Rumor.io

Alkermes

ALKS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,129

Bullish sentiment (50-day avg)88%

Price to earnings ratio105.7

Market capitalization6.7B

Earnings per share0.38

Dividend yield (TTM)—

Revenue (annual)1.5B

Net income (annual)241.7M

Social

What share of all stock conversation is about ALKS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Sep 21

Alkermes plc announced positive Phase 1b results for ALKS 7290, a treatment for attention-deficit hyperactivity disorder (ADHD), demonstrating clinical proof-of-concept and a clear early efficacy signal.
The study showed dose-dependent, clinically meaningful improvements on exploratory ADHD symptom measures in adults, with the higher dose reducing ADHD symptom severity by roughly half after just 14 days.
Alkermes is hoping ALKS 7290 could eventually become the company's first blockbuster, with Phase 2 data expected in 2027, and the treatment's potential application extending beyond ADHD to other conditions such as executive dysfunction and autism.

Generated by AI

Sentiment

Of the messages about ALKS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	85.71% -14.29	90.1% +6.42
Bearish	—	0%	14.29% +14.29	9.9% -6.42

Bullish· Apr 27

Alkermes plc ($ALKS) has seen a 12% increase in share price following its Q1/22 financial results and reiterated FY/22 business outlook.
The company reported a 32% YoY gain in proprietary sales, contributing to its strong financial performance.
Alkermes plc has received a positive analyst update, with Stifel Nicolaus raising its price target to $27.00.

Bearish· Feb 14

Analyst downgrades and price target reductions for Alkermes (ALKS) reflect bearish sentiment.
Alkermes' sales forecast for the year is no longer expected to rise, and its valuation has increased.
The company's forecast EPS has decreased, and Alkermes has reached a new 12-month low following analyst downgrades.

Generated by AI

Topics

Of the messages about ALKS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	81.82%	66.67%	21.23%
Technical Analysis	—	0%	16.67%	3.99%
Analysts	—	18.18%	16.67%	2.3%
Earnings	—	0%	0%	0.5%
Controversies	—	0%	0%	0.77%
Macro	—	0%	0%	71.23%

Earnings· Feb 14

Alkermes ($ALKS) reported earnings of $0.34, beating consensus estimates of $0.32.
The company's 4Q revenue was driven by significant upside from Ampyra royalties, while Vivitrol sales were 2% below consensus and Aristada sales were 12% above consensus.
Alkermes guided FY19 EPS below consensus but revenue above consensus, with updated guidance of $0.25-0.43 EPS and $1.14-1.19 billion in revenue.

Analysts· Feb 14

Alkermes plc ($ALKS) has been downgraded to Neutral by several analysts, including JPMorgan, BofA, and HC Wainwright.
Price targets for $ALKS have been lowered by various analysts, including HC Wainwright, Stifel Nicolaus, and JPMorgan.
Analysts have reaffirmed Buy ratings and Hold ratings for $ALKS, with Cowen reaffirming Buy and HC Wainwright maintaining a Hold rating.

Announcements· Nov 19

Alkermes plc ($ALKS) has increased its offer to acquire Avadel Pharmaceuticals plc ($AVDL) to $22.50 per share, consisting of $21 in cash and a $1.5 CVR tied to FDA approval of LUMRYZ.
The deal values Avadel at approximately $2.37 billion and sets up one of 2025's biggest biotech bidding battles, with Lundbeck's $2.4B bid being considered "superior" by Avadel's Board.
Alkermes has already raised its proposal to $2.37B, and Avadel has accepted the revised offer, beating out Lundbeck's challenge.

Generated by AI

Community

Of the messages about ALKS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	81.03%	40.32%	26.78%
Newcomers	—	18.97%	59.68%	73.22%

Regulars· Sep 21

The Phase 1b results for ALKS 7290 demonstrated a dose-dependent, clinically meaningful improvement in ADHD symptom measures in adults.
Alkermes' orexin agonist, ALKS 7290, showed a clear early efficacy signal in treating adult ADHD, with potential for advancement to later-stage reads and future upside interest.
The positive Phase 1b results support the potential for ALKS 7290 to become a company-changing blockbuster, with Alkermes hoping to use it for treating ADHD and potentially even autism.

Newcomers· Mar 31

New investors are comparing ALKermes ($ALKS) to Cintana ($CNTA), seeking an introduction to why CINTA is preferred over ALKS.
Some users are asking for investment goals or advice from others who own shares in ALKermes ($ALKS) and other companies.
Market indicators suggest a bull signal for ALKermes ($ALKS), with the stock sitting above its 50-day EMA and a strong trend in various technical analysis metrics.

Generated by AI

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]

4d agoYahoo Finance

Goldman Sachs resumes Alkermes stock coverage with neutral rating

6d agoInvesting.com

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

6d agoSeeking Alpha

Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290

In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...

7d agoYahoo Finance

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

7d agoYahoo Finance

Exclusive BAC Article: Alkermes; Positive Phase 1b POC Data ALKS 7290 ADHD, Phase 2 Data 2027, Ongoing Phase 3 Alixorexton Studies, And Catalysts (NASDAQ:ALKS)

8d agoSeeking Alpha

Also Discussed

Investors talking about ALKS also mention

#	Name	Attention
1	Agios Pharmaceuticals, Inc.AGIO	0%0
2	BioMarin Pharmaceutical IncBMRN	0%+0
3	Jazz Pharmaceuticals plcJAZZ	0%0
4	Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD	0%new
5	Ionis Pharmaceuticals, Inc.IONS	0%new
6	Acadia Pharmaceuticals Inc.ACAD	0%+0
7	Alnylam Pharmaceuticals, Inc.ALNY	0%0
8	Incyte Corp.INCY	0%new
9	Biogen IncBIIB	0%-0.01
10	Amgen Inc.AMGN	0.01%+0

Alkermes plc

Healthcare
Drug Manufacturers - Specialty & Generic

Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company works across research, clinical development, and product commercialization, using its drug formulation and delivery capabilities to support therapies designed for complex and chronic illnesses. Alkermes plc serves patients, healthcare providers, and healthcare systems in the United States, Ireland, and international markets. Founded in 1987 and headquartered in Dublin, Ireland, the company holds a notable position in the neuroscience-focused biopharmaceutical sector.

Website

Location

Connaught House

Dublin, D04 C5Y6

Ireland

Social

What share of all stock conversation is about ALKS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Sep 21

Alkermes plc announced positive Phase 1b results for ALKS 7290, a treatment for attention-deficit hyperactivity disorder (ADHD), demonstrating clinical proof-of-concept and a clear early efficacy signal.
The study showed dose-dependent, clinically meaningful improvements on exploratory ADHD symptom measures in adults, with the higher dose reducing ADHD symptom severity by roughly half after just 14 days.
Alkermes is hoping ALKS 7290 could eventually become the company's first blockbuster, with Phase 2 data expected in 2027, and the treatment's potential application extending beyond ADHD to other conditions such as executive dysfunction and autism.

Generated by AI

Sentiment

Of the messages about ALKS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	85.71% -14.29	90.1% +6.42
Bearish	—	0%	14.29% +14.29	9.9% -6.42

Bullish· Apr 27

Alkermes plc ($ALKS) has seen a 12% increase in share price following its Q1/22 financial results and reiterated FY/22 business outlook.
The company reported a 32% YoY gain in proprietary sales, contributing to its strong financial performance.
Alkermes plc has received a positive analyst update, with Stifel Nicolaus raising its price target to $27.00.

Bearish· Feb 14

Analyst downgrades and price target reductions for Alkermes (ALKS) reflect bearish sentiment.
Alkermes' sales forecast for the year is no longer expected to rise, and its valuation has increased.
The company's forecast EPS has decreased, and Alkermes has reached a new 12-month low following analyst downgrades.

Generated by AI

Topics

Of the messages about ALKS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	81.82%	66.67%	21.23%
Technical Analysis	—	0%	16.67%	3.99%
Analysts	—	18.18%	16.67%	2.3%
Earnings	—	0%	0%	0.5%
Controversies	—	0%	0%	0.77%
Macro	—	0%	0%	71.23%

Earnings· Feb 14

Alkermes ($ALKS) reported earnings of $0.34, beating consensus estimates of $0.32.
The company's 4Q revenue was driven by significant upside from Ampyra royalties, while Vivitrol sales were 2% below consensus and Aristada sales were 12% above consensus.
Alkermes guided FY19 EPS below consensus but revenue above consensus, with updated guidance of $0.25-0.43 EPS and $1.14-1.19 billion in revenue.

Analysts· Feb 14

Alkermes plc ($ALKS) has been downgraded to Neutral by several analysts, including JPMorgan, BofA, and HC Wainwright.
Price targets for $ALKS have been lowered by various analysts, including HC Wainwright, Stifel Nicolaus, and JPMorgan.
Analysts have reaffirmed Buy ratings and Hold ratings for $ALKS, with Cowen reaffirming Buy and HC Wainwright maintaining a Hold rating.

Announcements· Nov 19

Alkermes plc ($ALKS) has increased its offer to acquire Avadel Pharmaceuticals plc ($AVDL) to $22.50 per share, consisting of $21 in cash and a $1.5 CVR tied to FDA approval of LUMRYZ.
The deal values Avadel at approximately $2.37 billion and sets up one of 2025's biggest biotech bidding battles, with Lundbeck's $2.4B bid being considered "superior" by Avadel's Board.
Alkermes has already raised its proposal to $2.37B, and Avadel has accepted the revised offer, beating out Lundbeck's challenge.

Generated by AI

Community

Of the messages about ALKS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	81.03%	40.32%	26.78%
Newcomers	—	18.97%	59.68%	73.22%

Regulars· Sep 21

The Phase 1b results for ALKS 7290 demonstrated a dose-dependent, clinically meaningful improvement in ADHD symptom measures in adults.
Alkermes' orexin agonist, ALKS 7290, showed a clear early efficacy signal in treating adult ADHD, with potential for advancement to later-stage reads and future upside interest.
The positive Phase 1b results support the potential for ALKS 7290 to become a company-changing blockbuster, with Alkermes hoping to use it for treating ADHD and potentially even autism.

Newcomers· Mar 31

New investors are comparing ALKermes ($ALKS) to Cintana ($CNTA), seeking an introduction to why CINTA is preferred over ALKS.
Some users are asking for investment goals or advice from others who own shares in ALKermes ($ALKS) and other companies.
Market indicators suggest a bull signal for ALKermes ($ALKS), with the stock sitting above its 50-day EMA and a strong trend in various technical analysis metrics.

Generated by AI

Alkermes

Social

Sep 21

Bullish· Apr 27

Bearish· Feb 14

Earnings· Feb 14

Analysts· Feb 14

Announcements· Nov 19

Regulars· Sep 21

Newcomers· Mar 31

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

Exclusive BAC Article: Alkermes; Positive Phase 1b POC Data ALKS 7290 ADHD, Phase 2 Data 2027, Ongoing Phase 3 Alixorexton Studies, And Catalysts (NASDAQ:ALKS)

Also Discussed

Alkermes plc

Company Information

Location

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

Exclusive BAC Article: Alkermes; Positive Phase 1b POC Data ALKS 7290 ADHD, Phase 2 Data 2027, Ongoing Phase 3 Alixorexton Studies, And Catalysts (NASDAQ:ALKS)

Also Discussed

Social

Sep 21

Bullish· Apr 27

Bearish· Feb 14

Earnings· Feb 14

Analysts· Feb 14

Announcements· Nov 19

Regulars· Sep 21

Newcomers· Mar 31